* If you want to update the article please login/register
Background With the optimal treatment undefined, a higher grade neuroendocrine neoplasm continues to pose a treatment haze. Methods NET001 and NET002 are phase II studies looking at avelumab. Patients with unresectable and/or metastatic WHO G2-3 NENs from a gastroenteropancreatic source or a bronchial primary and 0-2 prior lines of systemic therapy were eligible patients. Patients were injected with avelumab 10 mg/kg intravenously every two weeks for 26 cycles. NET001 investigated G3 poorly differentiated GEP neuroendocrine carcinomas and bronchial small/large cell NEC, but NET002 investigated G2-3 well-differentiated GEPNETs and bronchial atypical carcinoids, whereas NET001 investigated G3 poorly differentiated GEP neuroendocrine carcinomas and bronchial small/large cell NEC, whereas NET002 investigated G3 poorly differentiated GEP neuroendocinoids in NET001, a typical carcint endocindocin bronchial small/large cell NEC, nial NEC, cellular NEC, cyton atypical carcinoids in atypical carcinoids and atypical carcinoids, atypical carcinoids and atypical carcinoids and bronchial atypical carcinoids, bronchial Results Twenty-seven patients were enrolled; median age 64; 30% ECOG PS 1-2 and 78% were treated with 1+ lines of prior therapy. In 33% of patients, stable disease was present in 33%, and the disease control rate at 6 mo was 21%. Conclusion In patients with G2-3 NENs, single-agent PD-L1 blockade with avelumab showed limited antitumour activity.
Source link: https://europepmc.org/article/MED/35504244
Neuroendocrine tumors are a rare subset of tumors that have risen in incidence over the past four decades. Patients with gastroenteropancreatic neuroendocrine tumors have liver metastases during their clinical course, with up to 90% of patients with gastroenteropancreatic neuroendocrine tumors presenting liver metastases during their clinical course. NeLM's development requires biopsy to determine tumor grade, cross-sectional imaging to delineate the presence and number of metastases, and hormonal testing to determine tumor function. All these aspects should be considered during the multidisciplinary treatment of patients with NeLM.
Source link: https://europepmc.org/article/MED/35476146
The transition from metastasis to parotid gland appears mainly from head and neck region skin cancers. About 29% of parotid neoplasms were malignant, with 70 cases of parotid primary malignant tumors and 50 cases of metastases to parotid glands in a total sample. Around 78% of the cases were related to metastatic tumors to the parotid glands, squamous cell carcinoma, and melanoma of the head and neck region. The most common primaries were poorly differentiated neuroendocrine carcinoma of lung, with 4 cases of small cell carcinoma and one case of large cell neuroendocrine carcinoma. Merkel cell carcinoma was the second most common secondary tumor in the United States, with one case of direct invasion from overlying skin. Metastatic neuroendocrine carcinomas to the parotid gland account for around 22% of all metastatic tumors to the organ, according to our findings.
Source link: https://europepmc.org/article/MED/35466730
Dual tracer PET/CT exams have become a common treatment for metastatic Neuroendocrine neoplasms management, and it demonstrates the benefits of deciphering tumor molecular PET characteristics in patient care. This concept is expanded on in the case-example of incidentally finding 18 F-FDG avid metachronous lung carcinoma in a patient of metastatic well differentiated gastric NEN, wherein dual tracer PET/CT testing revealed FDG avid but non-68 Gaopacity avid lung opacity but non-68 Gada opacity.
Source link: https://europepmc.org/article/MED/35440472
In cell lines and a small number of primary tumors, molecular subtypes of small cell lung cancer characterized by the expression of key transcription regulators have been recently developed. Unknown information regarding the clinical and biological effects of neuroendocrine subtypes in metastatic SCLC, as well as the degree to which they differ within and between patient tumors and in patient-derived models is unknown. Transcriptomic analysis confirms previously identified subtypes based on ASCL1, NEUROD1, POU2F3, YAP1, and ATOH1 expression, and reveals a clinical subtype with mixed NE and non-NE phenotypes, marked by chemotherapy resistance and exceedingly poor outcomes. NE tumors are more likely to have RB1, NOTCH, and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies than traditional therapies. The observed differences in transcriptional consistency between patient tumors and model systems are likely to have a role in the design of novel therapeutic agents.
Source link: https://europepmc.org/article/MED/35440132
In France, pancreatic neuroendocrine tumors were treated with sunitinib and everolimus for the treatment of progressive, unresectable, or metastatic pancreatic neuroendocrine tumors. According to standard pNET treatments of chemotherapies and somatostatin analogues that had not previously approved by the health authorities, OPALINE was set up as an observational research to determine the safety of sunitinib and everolimus compared to standard pNET treatments of chemotherapies and somatostatin analogues. Methods of Data Analysis The OPALINE study evaluated the safety, disease development, and tolerance of everolimus and sunitinib. At least one targeted therapy was given to patients during their care journeys. During the follow-up illustrating the positive treatment tolerability over time, most patients receiving TTs did not change their dose. Conclusion Given their high tolerance and positive influence on estimated OS, the two TTs play a significant part in the care pathway for patients with pNETs.
Source link: https://europepmc.org/article/MED/35419649
BACKGROUND TRACY The aim of this phase I/III research was conducted to determine streptozocin's safety, quality, and pharmacokinetics in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. Methods Two patients received up to four cycles of intravenous STZ at 500 mg/m2 once a day for five days in a row or 1000 mg/m2 once a week for six weeks. Only 1 had non-evaluable disease in 17 patients, with partial response in 2, stable disease in 17, non-complete response/non-progressive disease in 17, non-complete response/non-protestable disease in 2, and none in 17 had non-evaluable disease. However, no adverse events were reported in any of 22 patients, including 17 grade 3 adverse events in 11 patients; however, no grade 4 or 5 adverse events were reported. STZ can be a helpful treatment for Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.
Source link: https://europepmc.org/article/MED/35411926
Background & Overview Neuroendocrine tumors with a diameter 10 mm are thought to be at a low risk of lymph node metastasis. Here we present a case of lymph node metastasis in a patient with a 4-mm NET who was classed as grade 2 here. The case was presented in the following way: After a positive fecal occult blood test, a 32-year-old woman was admitted to our hospital. After endoscopic subcutaneous resection with ligation, there were no residual tumor cells in the scar. Should G2 neuroendocrine tumors smaller than 5 mm be surgically resected? Conclusions We found a rare occurrence of a small NET with lymph node metastasis that was treated by robotic-assisted laparoscopic low anterior resection with lymph node dissection. Even though the threat of lymph node metastasis is remote, additional surgery is an option to be considered for grade 2 NET.
Source link: https://europepmc.org/article/MED/35429783
Neuroendocrine neoplasms develop in the gastrointestinal tract and are characteristic of the site of origin, such as the pancreas and small intestinal intestine, with predominant neuroendocrine differentiation. Neuroendocrine breast carcinoma is a rare disease. During routine screening mammography, a 60-year-old woman was discovered to have a solid left breast nodule. Tissue biopsy was determined to be normal with metastatic NEBC. On further diagnostic procedures, the patient was found to have primary small intestine asymptomatic NENs. Gastroenteropancreatic NENs are treated with long-acting somatostatin analogs with positive prognostic results.
Source link: https://europepmc.org/article/MED/35449642
Pancreatic neuroendocrine tumors are a common problem. As dedicated systemic therapies have developed recently and demonstrated results in randomized trials, an ongoing debate has arisen in the metastatic setting. If the tumor has a favorable prognosis, liver surgery is a viable option for advanced pNETs, as shown by a low to moderate proliferation index. In a multidisciplinary tumor board, the best option for an individual patient's treatment plan should be considered.
Source link: https://europepmc.org/article/MED/35326628
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions